LGALS3 and breast carcinoma: Furthermore, soluble galectin-3 has been described to be highly secreted by breast cancer and TNBC cells and to be associated with chemotherapy resistance and immunosuppression, suggesting galectin-3 as a diagnostic marker and a potential therapeutic target in BC development and progression [49,50].